Patents by Inventor Yves Gareau

Yves Gareau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF
    Publication number: 20230357221
    Abstract: Heterocyclic compounds of Formula I: and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Application
    Filed: June 28, 2023
    Publication date: November 9, 2023
    Inventors: Yves GAREAU, Stéphane GINGRAS, Yves CHANTIGNY, Gaoqiang YANG, Guy SAUVAGEAU, Irène BACCELLI, Anne MARINIER
  • Heterocyclic mitochondrial activity inhibitors and uses thereof
    Patent number: 11760754
    Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: September 19, 2023
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
  • HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF
    Publication number: 20210387980
    Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Application
    Filed: November 2, 2018
    Publication date: December 16, 2021
    Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
  • Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
    Patent number: 10647718
    Abstract: Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations. Particularly, the hematopoietic cells are human cells. The compounds are also useful in the medical treatment of hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immune-deficient disease in a subject.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: May 12, 2020
    Assignee: UNIVERSITÉDE MONTRÉAL
    Inventors: Guy Sauvageau, Yves Gareau, Stéphane Gingras
  • Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
    Patent number: 10336747
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 2, 2019
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Guy Sauvageau, Yves Gareau, Rejean Ruel, Stephane Gingras, Iman Fares
  • Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
    Patent number: 10035813
    Abstract: In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: July 31, 2018
    Assignee: Debiopharm International SA
    Inventors: John J. Partridge, John Colucci, Yves Gareau, Michel Therien, Robert Zamboni, Barry Hafkin, Anthony Marfat, Helmi Zaghdane
  • PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS
    Publication number: 20170334904
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Application
    Filed: December 2, 2016
    Publication date: November 23, 2017
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Guy SAUVAGEAU, Yves GAREAU, Rejean RUEL, Stephane GINGRAS, Iman FARES
  • COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS
    Publication number: 20170037047
    Abstract: Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations. Particularly, the hematopoietic cells are human cells. The compounds are also useful in the medical treatment of hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immune-deficient disease in a subject.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 9, 2017
    Inventors: Guy SAUVAGEAU, Yves GAREAU, Stéphane GINGRAS
  • Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
    Patent number: 9409906
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: August 9, 2016
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Yves Gareau, Réjean Ruel, Stéphane Gingras, Iman Fares
  • PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS
    Publication number: 20160222017
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Application
    Filed: February 18, 2016
    Publication date: August 4, 2016
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Guy SAUVAGEAU, Yves GAREAU, Rejean RUEL, Stéphane GINGRAS, Iman FARES
  • Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
    Patent number: 9296744
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 29, 2016
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Yves Gareau
  • PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE
    Publication number: 20150065415
    Abstract: In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Inventors: John J. Partridge, John Colucci, Yves Gareau, Michel Therien, Robert Zamboni, Barry Hafkin, Anthony Marfat, Helmi Zaghdane
  • PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS
    Publication number: 20150011543
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 8, 2015
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Yves Gareau
  • Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
    Patent number: 8901105
    Abstract: In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: December 2, 2014
    Assignee: Debiopharm International SA
    Inventors: John J. Partridge, John Colucci, Yves Gareau, Michel Therien, Robert Zamboni, Barry Hafkin, Anthony Marfat, Helmi Zaghdane
  • PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE
    Publication number: 20140051666
    Abstract: In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1, 8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 20, 2014
    Applicant: AFFINIUM PHARMACEUTICALS, INC.
    Inventors: John J. Partridge, John Colucci, Yves Gareau, Michel Therien, Robert Zamboni, Barry Hafkin, Anthony Marfat, Helmi Zaghdane
  • BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS
    Publication number: 20130244929
    Abstract: The present invention provides novel lipoglycopeptide compounds which are Type 1 signal peptidase inhibitors (SpsB). Compounds of the present invention are useful for the treatment of various bacterial related infectious diseases, particularly when used as a potentiator of a ?-lactam antibiotic such as imipenem and ertapenem. Accordingly, the present invention provides a method for the treatment of bacterial related infections using the compounds described herein, either alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: March 4, 2011
    Publication date: September 19, 2013
    Inventors: Michel Gallant, Karine Villeneuve, Patrick Beaulieu, Joel Robichaud, Helene Juteau, Yves Gareau, Sherman T. Waddell, Nancy Kevin, Xin Gu, Joann Huber, Michael J. Salvatore, JR., Kenneth Wilson, Scott K. Smith, Deborah Zink
  • HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
    Publication number: 20120010186
    Abstract: Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.
    Type: Application
    Filed: March 18, 2010
    Publication date: January 12, 2012
    Applicant: MERCK FROSST CANADA LTD.
    Inventors: Nicolas Lachance, Serge Leger, Renata M. Oballa, David Powell, Geoffrey K. Tranmer, Evelyn Martins, Yves Gareau
  • Pharmaceutical phenylquinoline and chromen-2-one triazole compounds
    Patent number: 7960409
    Abstract: The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: June 14, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Erich L. Grimm, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Yves Gareau
  • SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY
    Publication number: 20100298347
    Abstract: Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.
    Type: Application
    Filed: December 1, 2008
    Publication date: November 25, 2010
    Applicant: MERCK FROSST CANADA LTD
    Inventors: Michel Belley, Denis Deschenes, Rejean Fortin, Jean-Francois Fournier, Sebastien Gagne, Yves Gareau, Jacques Yves Gauthier, Lianhai Li, Joel Robichaud, Michel Therien, Geoffrey K. Tranmer, Zhaoyin Wang
  • SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY
    Publication number: 20100179173
    Abstract: Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and Metabolic Syndrome.
    Type: Application
    Filed: June 26, 2008
    Publication date: July 15, 2010
    Inventors: Daniel Guay, Christian Beaulieu, Michel Belley, Sheldon N. Crane, Jeancarlo De Luca, Rejean Fortin, Yves Gareau, Lianhai Li, Michel Therien, Geoffrey K. Tranmer, Vouy Linh Truong, Zhaoyin Wang